Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027

Caribou Biosciences, Inc.

Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.
Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.
Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.
Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.